SUMMARY
INTRODUCTION

CD4
+ T helper cells are central to the development of adaptive immune responses for the protection against infection and possibly malignancy by activating antigen-specific effector cells (CTL and B cells) and recruiting cells of the innate immune system such as macrophages and mast cells [1] [2] [3] [4] . Two predominant CD4 + T helper cell subtypes exist, Th1 and Th2, each with a unique role in the type of the global immune response elicited. Th1 cells, characterized by secretion of IFN-g and TNF-a , are primarily responsible for activating and regulating the development and persistence of cell-mediated (i.e. CTL) immunity [1] . In contrast, Th2 cells are responsible for the development of a broad therapeutic humoral response. Because of the central role of Th1 cells in cell-mediated immunity, there has been recent interest in developing adoptive T cell therapy for the treatment of malignancy using CD4 + T helper cells. However, the ex vivo expansion of human tumour antigen-specific CD4 + T helper cells has not been well defined and the elucidation of improved culture conditions for the ex vivo expansion of CD4 + T cells is an important issue [5] . Currently used ex vivo culture conditions are often inadequate for expansion of CD4 + T cells. The manipulation of the cytokines in the culture medium is one technique that is rigorously being explored for specifically expanding certain T cell subsets. The most common cytokine to be added to T cell cultures is IL-2. However, antigen specificity is often lost when using IL-2 alone for the generation of tumour antigen-specific CD4 + T helper cells, particularly when antigenspecific T cell precursors are low [5] [6] [7] . Another cytokine that has been extensively characterized over the past decade and which could be useful for the ex vivo expansion of human tumour-antigen-specific T cells for adoptive T cell therapy is IL-12. IL-12 is a cytokine that is uniquely different from other commonly used cytokines, such as IL-7, in that it only acts on activated T cells [8] . While the effects of IL-12 are well characterized on the ex vivo expansion of antigen-specific CD8 + T cells [9, 10] less is known about the role of IL-12 during the ex vivo expansion of CD4 + T cells, particularly T cells specific for tumour antigens.
In the present study, the in vitro effects of IL-12, along with IL-2, on CD4 + T cell line growth, phenotype, and antigen-specific function were evaluated. HER-2/neu peptide, p776-790 [11] was used as a model to study the role of IL-12 during in vitro cell growth of antigen-specific CD4 + T cells.
MATERIALS AND METHODS
Materials
All peptides were > 95% purity and manufactured by United Biochemical Inc. (Seattle, WA, USA). HER-2/neu peptides used were p42-56 (p42), HLDMLRHLYQGCQVV and p776-790 (p776), GVGSPYVSRLLGICL [12] . Nitrocellulose-backed plates were purchased from Millipore Corp (Bedford, MA, USA). Anti-IFN-g monoclonal antibodies were purchased from Mabtech (Nacka, Sweden). IL-12 (batch # 4D18I002, 1·7 ¥ 10 7 U/ mg) was a generous gift from the Genetics Institute (Cambridge, MA, USA). Anti-CD8, anti-CD4, anti-ab -TCR, anti-CD3, anti-TNF-a antibodies and purified recombinant human TNF-a were from Pharmingen (San Diego, CA, USA), streptavidin-alkaline phosphatase and alkaline-phosphatase colour detection reagents from Bio-Rad Laboratories (Hercules, CA, USA), human AB + serum from Valley Biomedical, Incorporated (Winchester, VA, USA), and Immulon IV ELISA plates from Dynex Technologies (Chantilly, VA, USA). TMB peroxidase substrate was obtained from Kirkegaard and Perry Laboratories (Gaithersburg, MD, USA) and streptavidin-horseradish peroxidase was obtained from Amersham Pharmacia Biotech (Uppsala, Sweden).
Source and preparation of PBMC
Breast cancer patients participating in a Phase I trial of HER-2/ neu peptide vaccines were leukapheresed at the completion of the trial after informed consent. PBMC derived from those leukaphereses were used in these studies [12] . PBMC were isolated by density gradient centrifugation as previously described [12] . Cells were aliquoted and cryopreserved in liquid nitrogen in freezing media (90% fetal bovine serum and 10% dimethylsulfoxide) at a cell density of 25-50 ¥ 10 6 cells/ml. PBMC from HER-2/neu immunized patients were used because PBMC from naïve cancer patients or normal healthy volunteers would require multiple labourious in vitro stimulations as we have previously reported [13] .
In vitro stimulation (IVS) of PBMC with peptide
In all experiments, except as indicated, PBMC were stimulated in vitro for 12 days in the presence of p776 peptide. For each experiment, 40-80 ¥ 10 6 cryopreserved cells were rapidly thawed, washed 2 times in 10 mls of RPMI-1640 containing streptomycin, penicillin, and 10% human AB serum (complete medium), and resuspended at 1·0-2·0 ¥ 10 6 cells/ml in the same medium and incubated in a humidified incubator at 37 ∞ C at 5% CO 2 . Peptide was added on day 0 to a concentration of 10 m g/ml. Ten U/ml of IL-2 and 0·01-10 ng/ml of IL-12 were added on days 4 and 8 and the cells were further incubated for 4 days. Viable cell yield was assessed by standard Trypan Blue exclusion.
T-lymphocyte proliferation
Thymidine incorporation was measured as previously described [14] . The generation of immune responses by peptide vaccination were detected from PBMC samples and presented as the mean of 24 well replicates, each well containing 2·5 ¥ 10 5 cells. The detection of proliferation following IVS is presented as the mean SI of 3-6 replicate wells each containing 7·5 ¥ 10 4 cells. Autologous irradiated (3300 rad) PBMC were added as antigen presenting cells at a 1 : 1 ratio with cultured T cells. Peptides were added into each well at concentrations indicated in each figure. No cytokines (i.e. IL-2 and IL-12) were added during proliferation assessment. The stimulation index (SI) was defined as the ratio of the mean of the experimental wells and the mean of control (no antigen) wells. SI's of greater than 2 were considered a positive proliferation response as previously described [12] .
Cytokine secretion
Following IVS, cells were restimulated with 10 m g/ml peptide and irradiated, autologous PBMC at 2·5 ¥ 10 5 /well for 40 h. No cytokines (i.e. IL-2 and IL-12) were added during restimulation. TNF-a content of the media was measured by ELISA. Immulon IV ELISA plates were coated with 50 m l of mouse anti-TNF-a monoclonal antibody at 2·5 m g/ml in carbonate buffer (15 m M Na 2 CO 3 , 35 m M NaH/CO 3 , pH 8·0). Wells were blocked 2 h at room temperature with 200 m l of PBS containing 1% BSA and 0·5% Tween-20. The plates were washed 4 times using PBS containing 0·1% Tween-20 (PBST). Cell culture supernatants were added at 100 m l/well and the plates were further incubated overnight at 4 ∞ C. The plates were washed 4 times with PBST. One hundred microliters PBST containing 10% goat serum and 0·5 m g/ml biotinylated anti-TNF-a antibody were added to wells and the plates were further incubated for 2 h at room temperature followed by washing 4 times with PBST. The plates were subsequently incubated with 100 m l/ well of PBS containing 1 : 3000 streptavidin-horseradish peroxidase, washed, and developed with 100 m l/well TMB peroxidase substrate. The developing reaction was terminated with 1 N hydrochloric acid and the OD was measured at 450 nm optical wavelength using a Molecular Devices (Sunnyvale, CA, USA) kinetic microplate reader . Purified TNF-a was analysed in parallel and the OD values of the samples were used to establish a standard curve (ng/ml).
Enzyme-linked immunosorbent spot (ELIspot)
An ELIspot assay (3-day format) was used to determine frequencies of peptide-specific T lymphocytes as previously described with only minor modifications (i.e. substituting MHC class I peptide with MHC class II peptide antigen) [14] . On day 1, T cells (3-6 replicates per condition) were plated into 96-well, anti-IFN-gcoated nitrocellulose plates in 100 m l media. The cells were stimulated with 100 m l of media containing a 1 : 1 ratio of autologous, irradiated (3000 rads) PBMC with or without antigen (10 m g/ml). The cells were further incubated for 20 h at 37 ∞ C and detection of bound IFN-g was performed as previously described [14] . Data is presented as the mean peptide-specific T cell frequency/million cells ( ± sem) calculated from 6 (patient 1276) or 3 replicates (patient 6622).
Flow cytometry
Flow cytometry of human T cells was done as previously described [14] . 
RESULTS
Generation of immunity to HER-2/neu helper peptide, p776-790, in patients with HER-2/neu-overexpressing tumours
Patients 1276 and 6622 were vaccinated with a HER-2/neu peptide-based vaccine consisting of helper peptides including p776 [15] . The patients had no detectable preexisting immunologic response to the p776 or the HER-2/neu ICD. However, after the immunizations were complete, patients had detectable p776-specific proliferation responses (Fig. 1) . Both patients also developed ICD-specific protein proliferation responses. The patients did not develop responses to another HER-2/neu-derived peptide, p42, which was not contained in the vaccine preparation. PBMC derived from each patient donor were used to assess the effects of IL-12 on antigen-specific T cell line expansion and phenotype using p776 as a model antigen.
The addition of IL-12 to IL-2 increases antigen-specifi c proliferation after IVS with HER-2/neu helper peptide
The addition of IL-12 to p776 antigen and IL-2 did not change the overall recovery of viable cells following IVS (Fig. 2a) . Furthermore, as expected, the cells were predominantly ( > 74%) CD3+/ CD4+ when incubated in the presence of p776 and either IL-2 alone or IL-2 and IL-12 (10 ng/ml) (Fig. 2b) . The phenotype was not significantly altered by the addition of IL-12. In similar experiments, but without MHC class II peptide, we also observed that CD3, CD4, and CD8 T cells were unaltered by the inclusion of IL-12 (data not shown). Proliferation was assessed following IVS of patient PBMC with p776, IL-2 and varying (0, 0·01, 0·1, 1, and 10 ng/ml) concentrations of IL-12. As shown in Fig. 3 , those cells expanded in culture in the presence of IL-2 alone, i.e. in the absence of IL-12, did not demonstrate a proliferative response to p776. That is, proliferation observed in the original samples before IVS was not preserved when using IL-2 alone. The addition of IL-12, during IVS, resulted in augmentation of antigenspecific proliferation in a dose-dependent manner. As an example, the SI of T cells taken through IVS in 10 ng/ml IL-12 was 16 in PBMC from patient 1276 (Fig. 3a) and 9 in PBMC from patient 6622 (Fig. 3b) . The proliferative responses were specific for the p776, as there was no proliferative response to the irrelevant HER-2/neu peptide, p42 (data not shown). The inclusion of IL-12 along with IL-2 during IVS substantially reduced nonspecific cellular proliferation (Fig. 3c,d ). The reduction in nonspecific cellular proliferation was similar at all concentrations of IL-12 used and was not dose-dependent within the range of IL-12 concentrations used. Results shown from 2 patients are representative of a minimum of 3 independent experiments from each patient. The observed effects were also observed in PBMC from at least 3 different patient donors.
The addition of IL-12 to IL-2 increases the number of peptide antigen-specific CD4 + T cells after IVS with HER-2/neu helper peptide
The T cell frequency was evaluated following IVS of patient PBMC with p776 and IL-2 in the absence or presence of IL-12 (Fig. 4) . Following IVS with peptide and IL-2 alone, the p776-specific and p42-specific T cell frequencies in PBMC from patient 1276 were 91 ± 22/million cells and 0/million cells, respectively (Fig. 4a) . The addition of IL-12 during IVS resulted in an increase of p776-specific T cells to 1003 ± 50/million cells. In the absence of IL-12 the T cell frequencies to p776 and p42 in PBMC from and HER-2/neu protein, ICD, in patients with HER-2/neu-overexpressing cancers. Patients were vaccinated with HER-2/neu peptides once a month for 6 months. Peptide-specific immunity was assessed prior to (Pre) and after vaccination (Post). T cell proliferation was assessed by 3 H-thymidine incorporation assays and stimulation index was calculated from 24-well replicates. ٗ p776-790 (immunizing peptide) response, p42-56 (irrelevant, nonimmunizing, HER-2/neu peptide) response, ICD response (protein). S.I.s greater than 2 (-----) are indicative of a positive proliferation response to antigens as described in the Materials and methods. All S.I.s greater than 2 were statistically significant ( P < 0·05) than control (no antigen) wells as assessed by unpaired 2-tailed student's T -test. patient 6622 were not detectable following IVS with p776 and IL-2 alone (Fig. 4b) . The inclusion of IL-12 resulted in increased p776-specific T cells to 272 ± 24/million cells. T cells specific for p42 were not elevated in PBMC from either patient as a result of inclusion of IL-12 during IVS (Fig. 4a,b) . T cell lines derived with IL-2 and IL-12 were 86% and 89% CD4 + for patients 1276 and 6622, respectively (data not shown). Results shown are representative data of at least 3 experiments in 3 different patients yielding similar data. Figure 4 demonstrates that IL-12 in culture can enhance tumour antigen-derived peptide-induced TNF-a release compared to cultures incubated in IL-2 alone. For patient 1276, the TNF-a yield from T cell lines established in p776 and IL-2 alone was 63 ± 7 pg/ ml and increased to 390 ± 33 pg/ml by the inclusion of IL-12 (Fig. 5a ). For patient 6622, the TNF-a yield from T cell lines established in p776 and IL-2 alone was not detectable and was increased to 9·5 ± 3 pg/ml for cells incubated by the inclusion of IL-12 (Fig. 5b) . Increased TNF-a release to the irrelevant HER-2/ neu peptide, p42-15, was not observed in PBMC in either patient (Fig. 5c,d) . Results shown are representative of 3 experiments yielding similar results.
The addition of IL-12 to IL-2 increases antigen-specifi c TNF-a release by T cells after IVS with HER-2/neu helper peptide
DISCUSSION
In general, active immunization of cancer patients with tumour antigen-specific vaccine does not result in regression or cure of existing malignancy. Most likely, the greatest utility of cancer vaccines will be in the prevention of cancer recurrence or even the initiation of disease. Infusion of competent antigen-specific T cells (i.e. adoptive T cell therapy) however, may result in eradication of cancer [16] . Successful ex vivo expansion of tumourspecific T cells for therapeutic use in humans has been limited by the lack of defined tumour antigens which would allow expansion of antigen-specific T cells, the understanding of the in vitro expansion requirement of T cells which would allow the generation of maximal numbers while retaining optimal antigen-specific function, and the ability to develop methods for ex vivo culture which could expand polyclonal T cell lines, both CD4 + and CD8 + . Recent studies in adoptive T cell therapy of malignant melanoma have demonstrated the potential utility of this approach. Dudley and colleagues evaluated the therapeutic efficacy of infusion of T cells expanded in the presence of tumour cell lysate [17] . In that study infusion of polyclonal cell lines resulted in approximately a 50% objective response rate. While the mechanism of tumour killing in this study was unclear, a reasonable hypothesis is that the cell lines had a strong CD4 + T cell component which resulted in direct CD4 + T cell killing of tumours, augmentation of endogenous or transferred CD8 + tumour-specific T cell immunity or both. In fact, in a similar parallel study by the same group, infusion of pure CD8 + T cell populations under the same conditions had little impact on tumour cell growth, suggesting that CD4 + T helper cells played an active role in anti-tumour immunity [18] .
It is well known that the CD4 + T cell is critical in controlling the activation and persistence of the immune response against viral infections [1, 19] . Recent evidence also suggests that CD4 + T cells are essential for anti-tumour immunity and for function and survival of tumour-specific CD8 + T cells [20] . In murine tumour models, lymphocyte depletion studies reveal that both CD8 + and CD4 + T cells are required for therapeutic efficacy [21] . In fact, CD4 + T cell-depleted mice showed faster tumour development than CD8 + -depleted mice suggesting a dominant role for CD4 + T cells [22] . The importance of CD4 + T cells in the evolution of the tumour-specific immune response is underscored by recent studies demonstrating that infusion of tumour antigen-specific CD4 + T cells can initiate a de novo tumour antigen-specific CTL response [23] . CD4 + T cells can also modify the immune microenvironment by producing cytokines that attract DC, macrophages, and eosinophils to promote an inflammatory environment [3] . In recent times, there have been increased efforts to identify tumour antigens and, in particular, tumour antigen MHC class II epitopes to generate a strong Th1 immune response. The generation of Th1 CD4 + T cell immunity may be particularly important for effective anti-tumour immunity as suggested by recent murine studies in which it was demonstrated that the Th1 phenotype is absolutely necessary for therapeutic efficacy of adoptive T cell therapy [24] . Additionally, Th1 CD4 + T cells are important for broadening the epitope recognition (i.e. epitope spreading) of the anti-tumour T cell repertoire and preventing the outgrowth of antigen-negative variants [25] .
HER-2/neu is a tumour antigen overexpressed by a wide variety of adenocarcinomas including breast and ovarian cancers. Active immunization of cancer patients with HER-2/neu helper peptide vaccines can boost antigen-specific T cell frequencies substantially in vivo [26] . We hypothesized that active immunization of cancer patients followed by ex vivo expansion of T cells may offer the clinical potential of increasing cancer-specific T cells to numbers greater than what could be achieved by vaccination alone. We evaluated ex vivo expansion of T cells specific for HER-2/neu helper epitopes as a model using IL-2 and IL-12 to augment T cell number and function. IL-12 has been well defined for ex vivo expansion of viral-specific CD8 + T cells. For example, the cytolytic activity of HIV-specific T lymphocytes is greatly enhanced by including IL-12 along with IL-2 during ex vivo expansion of T cells with HIV-derived antigens [27] . Less is known about a role for ex vivo expansion of CD4 + T cell lines ) were cultured with 10 mg/ml p776-790, 10 U/ml IL-2, and varying concentrations of IL-12 (0, 1, and 10 ng/ml). The cells were subsequently tested for TNF-a release against no antigen (none, squares), 10 mg/ml p776-790 (triangles) or 10 mg/ ml p42-56 (circles). Each determination is the average (± sem) for triplicate determination. *P = 0·004; **P = 0·04, compared to TNF-a release from cultures carried through IVS with IL-2 alone and subsequently restimulated with 10 mg/ml p776-790. The absence of an error indicates an standard error of the mean of less than 1%. Cells using IL-12 and specifically the generation of Th1 T cell lines reactive against human tumour antigens. Experiments, in the present study, demonstrated that inclusion of IL-12 along with IL-2 during the ex vivo expansion of human antigen-specific CD4 + T cells resulted in a significant increase in the blastogenic response to a subsequent rechallenge with antigen, the number of antigenspecific T cells, and augmented function of Th1 phenotype lymphocytes. These findings, however, are in contrast to the observed effects of IL-12 in vivo where profound suppression of the CD4 T helper cell population has been observed [28, 29] . The reason for this difference is unclear but likely is the effect of environmental differences such as the actions of IL-12 on other tissue types that interact with immune effectors. For example, other tissues respond to IL-12 such as hepatocytes which could lead to altered haematopoetic cells dynamics [30] . Whatever the mechanism, the suppressive effects of IL-12 in vivo also extend to the CD8 T cells, monocytes and neutrophils indicating a lack of specificity. Thus the in vitro effects of IL-12 on CD4 T cells may be markedly different than the effects in vivo.
The results presented here demonstrate that IL-12, when added to cell cultures during IVS with IL-2 and tumour antigen helper peptides promotes increased recovery of CD4 + T cells specific for HER-2/neu helper peptide. T cell lines incubated with antigen, IL-2 and IL-12 show augmented function and secretion of Th1 type cytokines. The resulting cultures, depending on the levels of antigen-specific T cell precursors, could be used directly for infusion or could be manipulated by further ex vivo expansion. Although it is not currently known how many tumour-antigen specific CD4 T cells would be needed to eradicate tumour, previous studies in murine models have shown that infusion of tumourspecific CD4 T cells at doses as low as 3 ¥ 10 5 CD4 T cells is effective at inhibiting tumour growth and eliciting an endogenous CD8 T cell response [23] . A number of other factors including tumour aggressiveness and disease burden would also greatly influence the amount of CD4 T helper cells required. Our findings could potentially be useful for translating adoptive T cell therapy to the clinic where increasing both numbers and function of polyclonal tumour antigen-specific Th1 CD4 + T cells may be important in mediating an anti-tumour response.
